key: cord-1020262-n9zxm3oy authors: Roncato, Rossana; Angelini, Jacopo; Pani, Arianna; Talotta, Rossella title: Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? date: 2022-03-04 journal: Biochim Biophys Acta Mol Cell Biol Lipids DOI: 10.1016/j.bbalip.2022.159140 sha: 8d5910efc564db9cc1b86c327d426c347ba0c40f doc_id: 1020262 cord_uid: n9zxm3oy Lipid rafts are nanoscopic compartments of cell membranes that serve a variety of biological functions. They play a crucial role in viral infections, as enveloped viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can exploit rafts to enter or quit target cells. On the other hand, lipid rafts contribute to the formation of immune synapses and their proper functioning is a prerequisite for adequate immune response and viral clearance. In this narrative review we dissect the panorama focusing on this singular aspect of cell biology in the context of SARS-CoV-2 infection and therapy. A lipid raft-mediated mechanism can be hypothesized for many drugs recommended or considered for the treatment of SARS-CoV-2 infection, such as glucocorticoids, antimalarials, immunosuppressants and antiviral agents. Furthermore, the additional use of lipid-lowering agents, like statins, may affect the lipid composition of membrane rafts and thus influence the processes occurring in these compartments. The combination of drugs acting on lipid rafts may be successful in the treatment of more severe forms of the disease and should be reserved for further investigation. compartments, and rafts may occasionally harbor atypical lipids such as gangliosides [26] . As mentioned earlier, cholesterol plays a critical role in increasing membrane fluidity, inducing coalescence of small rafts and increasing the size of raft domains. In addition, lipid rafts contain globular proteins that have various biological functions and are able to connect raft domains into larger platforms (>300 nm) [24] . Proteins can be bound to the lipid bilayer by lipid anchors: saturated lipids, generally found in rafts, anchor kinases and various transmembrane proteins [25, 27] Lipid rafts can also be detected in the membrane of cellular organelles, such as the endoplasmic reticulum (ER), endosomes and mitochondria. An interesting experiment performed in human fibroblasts showed that mitochondrial lipid rafts are involved in the early steps of autophagy [28] . In particular, mitochondrial ganglioside GD3 can interact with proteins of autophagy and its depletion can affect this process by altering ER mitochondria communication. Lipid rafts composition may also determine endosome maturation: the reduction of sterols in the endosomal membrane and the increase of bis(monoacylglycero)phosphate are associated with the transition from early to late endosomal stages [20] . However, the exact biochemical composition of lipid rafts in organelles is unclear and it seems that cholesterol would play a lesser role than in the plasma membrane. that is critical for viral membrane fusion and subsequent release of the viral RNA genome into the host cytoplasm. Although an in vitro study showed that ACE2 colocalizes with clathrin heavy chain in nonraft domains [41] and clathrin-mediated endocytosis is the best characterized route of entry for coronaviruses [30] , the bulk of evidence suggests that ACE2 and TMPRSS2 are located in lipid rafts [13, 14] and this may account for a preferentially caveolae-mediated transport of SARS-CoV-2 into target cells. A caveolae-mediated transport has been described for many viruses, such as Simian virus 40 (SV40), which can directly bind glycosphingolipids [42, 43] . Several studies in vitro have also shown that coronaviruses can infect cells through caveolae-mediated endocytosis [14, 30, 44, 45] . In this case, lipid rafts would play a central role especially in the early phase of viral infection. Interestingly, bioinformatic prediction models showed that SARS-CoV proteins, including the spike protein, contain at least 8 putative motifs that may interact with cav-1 [46] . It was also shown that replacement of ACE2 in a nonraft environment, after cholesterol depletion in Vero E6 cells, reduced pseudotyped SARS-CoV infectivity by 90% [14] . Unlike clathrin vesicles, which lose the clathrin envelope, caveosomes retain their caveolin content (and thus identity) when they fuse with endosomes, and this property appears to be critical in virus sorting [47] . Additionally, the small GTPase Rab5, which is associated with the plasma membrane and early endosomes, may determine the fate of the ligand in endosomes during both clathrin-and caveolae-mediated transport. Interestingly, clathrin-and caveolae-mediated endocytosis are two actively overlapping mechanisms and may inhibit each other [48] . Furthermore, preclinical evidence supports a close correlation between membrane cholesterol content, ATP-binding cassette transporter A1 (ABCA1) expression and predisposition to viral for the formation of virological synapses, virion reconstitution and assembly of env and gag proteins [50, 51] . However, the role of ABCA1 in SARS-CoV-2 infection is unknown. Using Vero E6 cells, Wang et al. showed that disruption of raft and nonraft cholesterol by methyl-βcyclodextrin (MβCD) inhibited SARS-CoV pseudovirus infectivity in Vero E6 cells in a dosedependent manner, whereas the use of filipin or nystatin, which interfere more specifically with caveolae formation, had no effect [2] . The authors also observed the absence of colocalization between the virus and cav-1 in the dual immunostaining assay, leading to the hypothesis that entry of the SARS-CoV pseudovirus may occur via a cholesterol-related pathway, independent of caveolae formation. Beside cholesterol, dynamin may also play a central role in classical endocytosis, caveolaemediated endocytosis or other non-canonical pathways of endocytosis that have been proposed as alternative mechanisms of viral entry [30, 52] . Drugs targeting dynamin may therefore disrupt the mechanism of viral internalization through either classical or non-classical pathways. To conclude, the scenario underneath SARS-CoV-2 entry into target cells is characterized by the concomitant exploitation of different pathways, including caveolae-and clathrin-mediated routes or other non-canonical transports. Lipid composition, particularly plasma membrane cholesterol content, and key proteins, like dynamin, could be of paramount importance in regulating these mechanisms, therefore representing potential pharmacological targets. The plasma membrane is responsible for both the interface with the external environment and the the immune response, by relocating and accumulating receptors in specific plasma membrane regions of immune cells [25] . Polyunsaturated fatty acids (PUFA) and cholesterol have been shown to contribute to the recruitment of key proteins in partitioned functional membrane domains. Acute cholesterol depletion, although not highly specific for lipid rafts, can activate some signaling pathways in human neutrophils, macrophages, and RBL-2H3 histamine-releasing cells [25] . Cholesterol present in lipid rafts may however regulate the shedding of lipid raft-associated proteins, including those responsible for cell adhesion and recruitment, cytokine signaling and apoptosis [53] . Cytokine receptor shedding can reduce cytokine signaling in target cells, but may also generate soluble receptors with agonistic or antagonistic effects [54] . For instance, cholesterol content in lipid rafts has been shown to be critical for shedding the receptors of interleukin-6 (IL-6) and tumor necrosis factor (TNF)- and for activating of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) cascade in macrophages, although it had no effects on cell adhesion and migration [55, 56] . It is known that IL-6 can bind the IL-6 soluble receptor and that this complex, circulating in the bloodstream, can eventually interact with a wide range of cells expressing the transmembrane receptor gp130 [57] . Furthermore, experiments on macrophages derived from mouse models have shown that the increase in serum and plasma membrane cholesterol may enhance the responsiveness of TLR2, TLR4, TLR7 and TLR9 to ligands [58] . Since TLR3, TLR7 and TLR9 are responsible for the recognition of viral nucleic acids, it is likely that an increase in free and membrane cholesterol could potentiate the antiviral response by mobilizing these receptors into lipid raft domains. preclinical studies on mouse models [59] . Extracellular acceptors of cellular cholesterol, such as lipid-free apoA-I and high-density lipoprotein (HDL), may further compromise raft domain integrity of immune cells and disrupt pro-inflammatory pathways depending on lipid raft [60] . The level of membrane cholesterol seems also to regulates the expression of ABCA1, which in turn is negatively associated with pro-inflammatory responses in macrophages following stimulation of TLR, including TLR7 and TLR9 [4] . The increase in cholesterol and raft formation has been associated with B and T lymphocyte activation [4] . Increased cholesterol content has been reported in T cells from patients with systemic lupus erythematosus (SLE), where it may promote hyperactivation of pro-inflammatory signaling pathways and the imbalance between Th17/T regulator (Treg) cell subsets [61] . Specifically, the exchange of BCR, TCR, TNF receptor-1 (TNFR1) and CD40 from nonraft to raft domains and changes in lipid rafts after the binding of costimulatory molecules, such as CD28 or cytotoxic Tlymphocyte-associated protein 4 (CTLA-4), would play a crucial role in the adaptive immune response [4, 62] . In addition, immunological and proliferative signaling pathways that develop through the interferon (IFN)-Janus kinase (JAK)-signal transducer and activator of transcription (STAT), transforming growth factor (TGF)-Smad and mitogen-activated protein (MAP) kinase signaling cascades would take place in lipid rafts and thus depend on adequate levels of membrane cholesterol [4] . However, other studies, based on different protocols and methodologies, have showed that moderate cholesterol depletion may induce the coalescence of lipid rafts in T cells and hence activate Ras-extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase signaling pathway [63, 64] . Caveolae are of major importance in immune synapses and have been identified in macrophages, neutrophils, endothelial cells, and fibroblasts but not in lymphocytes [25] . Cav-1, associated with lipid rafts, can interact with and affect the function of several proteins, promoting or downregulating the immune response. An example is the inhibition of the endothelial enzyme nitric oxide synthase (eNOS) by cav-1 SD [68] , thereby reducing the production of nitric oxide (NO), which in turn prevents the activation of neutrophils, mast cells and platelets, decreases TLR4 expression in the lungs and regulates the expression of CD14, CD36 and myeloid differentiation factor 88 (MyD88) in macrophages [4] . Notably, preclinical data have shown that the exposure of bovine aortic endothelial cells to high cholesterol concentration may reinforce the inhibitory activity played by cav-1 on eNOS, whereas statins would have the opposite role [69] . The overproduction of NO in cav-1 deficient endothelial cells could however determine the tyrosine nitration of mitochondrial respiratory chain components [70] , leading to reduced mitochondrial reserve capacity, oxidative stress, aerobic glycolysis, and inflammation through the activation of NF-kB and activator protein-1 (AP-1) by reactive oxygen species (ROS). DNA damage provoked by ROS may activate poly-ADP-ribose polymerase (PARP) proteins and induce the expression of genes involved in cellular proliferation, angiogenesis, inflammation, and fibroblast activation [70] . Deficiency in cav-1 has been associated with fibroblast recruitment and pulmonary fibrosis in mouse models and patients affected by systemic sclerosis (SSc) [71] , a scenario potentially mirroring the end stage of COVID-19 ARDS. ARDS may also follow a surfactant deficit and thus be the result of altered metabolism of phospholipids, which are the major components of surfactant [72] . Finally, recent studies have shown that cav-1 may bind several microRNAs (miRNAs) capable of regulating its activity in lipid rafts [4] . Interestingly, some of them, such as miR-138 and miR-199-5p, have been associated with the NF-kB pathway and lung fibrosis. Although experimental results are conflicting, the majority of studies agree that ACE2 is a lipid raft protein, supporting the view that virus entry would preferably occur in these membrane microdomains [14, 73, 74] . Additionally, the SARS-CoV-2 spike protein contains a lateral Nterminal domain (NTD), capable of binding gangliosides within lipid rafts, which may subsequently allow the receptor binding domain (RBD) to interact with ACE2 [75]. Interestingly, an infection assay with a SARS-CoV-2 spike-bearing pseudovirus revealed that virus entry into HEK293T cells was not dependent on dynamin, clathrin, or caveolin, whereas it was enhanced by cholesterol-rich lipid rafts [76] . The authors also observed that the depletion of cholesterol content in rafts could reduce the infectivity of SARS-CoV-2, similar to what observed in other experiments with coronaviruses [3, 14] . Other researchers have reported that disruption of lipid rafts-associated sphingolipids by a spray containing α-cyclodextrin could counteract the binding of the virus to ACE2 [77] . While the role of lipid rafts in mediating SARS-CoV-2 endocytosis is gradually becoming more clearly defined, the link between lipid rafts disruption and antiviral response toward SARS-CoV-2 is largely unexplored. The integrity of lipid rafts appears to be a prerequisite for an adequate immunosurveillance against pathogens. As discussed before, lipid composition and relocation of receptors or coreceptors from nonraft to raft membrane may modulate either the innate or acquired immune response as well as immunotolerance mechanisms, whose balance is crucially important in dictating the outcomes of COVID-19 [78] . Patients with severe COVID-19 were shown to have a decrease in the levels of high-density (HDL) cholesterol lipoproteins, CD8+ T lymphopenia or exhaustion and the hyperactivation of the innate immune response, occasionally culminating in a cytokine storm [79] . Therefore, targeting the immune response from a lipid raft perspective would be extremely difficult given the dual effect that these domains have in modulating innate and acquired immune cells as well as effector and regulatory elements of the immune response. [18, 80] . Interestingly, part of the mechanism of action of such agents may be explained on the basis of remodulation of target molecules in lipid rafts. Evidence in support of this will be discussed in the next sections. Glucocorticoids represent a reference class of drugs in the treatment of severe respiratory distress syndrome. Data from the RECOVERY [81] and SOLIDARITY [82] studies showed that dexamethasone was the only drug that reduced mortality in people with COVID-19, making it the first drug approved for the treatment of this disease. Although the results of more recent studies do not support the use of these drugs in the treatment of early and uncomplicated COVID-19 [18, 83] , the use of dexamethasone, along with other glucocorticoid molecules, can still be recommended in hospitalized patients with severe COVID-19 who require oxygen therapy (ranging from supplemental oxygen to mechanical ventilation) [80] . The early use of corticosteroids in SARS-CoV-2-positive patients is questionable due to their deleterious effect on immune response and viral clearance [84] . Similarly, there is no strong evidence to recommend corticosteroids in not severe J o u r n a l P r e -p r o o f Journal Pre-proof COVID-19, diabetic or immunocompromised patients [16] . All evidence from clinical trials refers to oral or intravenous administration for up to ten days, while there are no recommendations for the use of inhaled or transdermal corticosteroids or with different regimens in terms of dose, treatment initiation and/or duration [16] . Of note, the anti-inflammatory function of these drugs may depend in part on altering the lipid composition of immune cell membranes. An experiment performed on murine T cell hybridomas showed that steroids can increase membrane fluidity, reduce palmitic acid content, and repress TCR by interfering with signaling proteins localized in lipid rafts [85] . These effects occurred early and appeared to be mediated by non-genomic mechanisms, including binding of glucocorticoid receptors placed in the lipid raft of the membrane and associated with cav-1 [86] . hyperproduction of systemic cytokines [87] . Among these, IL-6 is a pro-inflammatory cytokine with a broad spectrum of activity. IL-6 promotes the development of innate and acquired immune responses and can also induce endothelial dysfunction, fatigue, anemia, thrombocytosis and hepatic release of acute phase proteins [88] . IL-6 inhibitors (e.g., sarilumab, tocilizumab, siltuximab) approved for the treatment of rheumatoid arthritis (RA) and other rheumatic diseases showed efficacy in case series of patients with severe COVID-19 and may be recommended in combination with dexamethasone in selected hospitalized patients experiencing rapid respiratory decompensation due to COVID-19 [80] . Indeed, the results of several studies suggest that critical hospitalized patients and overall most patients with severe or critical COVID-19 benefit in terms of mortality from the addition of tocilizumab or sarilumab to corticosteroids [81, 89] , with no differences in terms of efficacy or safety between the two IL-6R inhibitors [89, 90] . The effect of IL-6 inhibitors on lipid raft integrity and composition is not clear. In studies conducted in RA cohorts of patients, treatment with IL-6 inhibitors has been associated with increased blood J o u r n a l P r e -p r o o f HDL/low density lipoprotein (LDL) ratios and reduced levels of pro-inflammatory markers, such as C-reactive protein (CRP) [91, 92] . It may be postulated that the increased availability of circulating cholesterol would influence lipid rafts composition and membrane fluidity, which ultimately would have an anti-inflammatory effect. The JAK-STAT pathway consists of a signaling cascade that mediates the action of various cytokines and growth factors [93, 94] . JAK-inhibitors (JAKi), such as baricitinib, tofacitinib and ruxolitinib, are recommended in COVID-19 management as these drugs can counteract the development of cytokine storm, while preventing the angiotensin II-angiotensin receptor-1 (AT-1) signaling pathway, which has been associated with ARDS and worse disease outcomes [95] . In addition, JAKi interfere with viral endocytosis by controlling the AP2-associated protein kinase 1/cyclin-G-associated kinase-pathway [83] . Notably, it has been shown that the assembly of lipid rafts in response to the binding of cytokines to their receptors precedes the activation of the JAK/STAT signaling cascade in human lymphocytes [96] . Treatment with JAKi in patients affected by RA has been associated with increases in blood LDL and HDL [97] , and experiments in vitro have shown that tofacitinib, a pan-JAKi, can inhibit intracellular lipid accumulation in macrophages by upregulating the expression of ABCA1 [98] . It is plausible that JAKi may affect the raft composition of organelles and the plasma membrane, which in turn is critical for their biological effects, but whether this event could affect the viral lifecycle or clearance is unknown. Consistently, WHO guidelines strongly recommend baricitinib in case of severe o critical COVID-19, as an alternative to IL-6 inhibitors, while they make a conditional recommendation against other JAKis, due to limited data from clinical trials [18] . J o u r n a l P r e -p r o o f Immunotherapies that neutralize IL-1, such as anakinra, have been used with success in cases of COVID-19 complicated by systemic inflammation [99] . These agents are approved for RA and autoinflammatory syndromes. To our knowledge, there is no evidence linking IL-1 antagonists to lipid rafts, although IL-1 signaling requires a lipid raft-mediated mechanism to generate oxidative stress and systemic inflammation [100] . Prenylation of RhoA kinase is an important step in preventing the activation of inflammasome platforms that precede the proteolytic activation of IL-1β. Deficient prenylation of RhoA kinase may be a risk factor for autoinflammation [101] . However, prenylation would occur in domains other than lipid rafts [102] . Antimalarials are lipophilic and weak basic compounds used in the treatment of rheumatic diseases [103] . The use of antimalarials such as hydroxychloroquine or chloroquine has been considered for prevention and treatment of COVID-19 [104] , but eventually not recommended by most recent evidence [18] . However, a number of interesting observations indicate that these medications may prevent some steps of viral infection via a lipid raft-mediated pathway. These mechanisms may include: modification of lysosomal pH and interference with intracellular TLR function, the improvement in lipid profile [105] [106] [107] , and the competition for the binding of sialic acid and gangliosides placed in lipid rafts with the NTD domain of the spike protein [108]. The European Medicines Agency (EMA) and the FDA granted conditional approval for the antiviral treatment remdesivir for the treatment of patients with severe COVID-19 who require oxygen therapy, excluding patients on high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation [18, 109] . However, remdesivir cannot be considered an established standard of care because currently available data are inconsistent and overall show no clear clinical benefit in terms of mortality or use of mechanical ventilation [17, 18] . In addition to its main mechanism of action, which is inhibition of the viral RNA-dependent RNA polymerase, remdesivir may also synergize with NPC1-inhibitors in regulating the lysosomal trafficking of cholesterol and sphingolipids [40] . Conversely, there is a strong recommendation against the use of the anti-retroviral protease inhibitor lopinavir, alone or in combination with ritonavir, for SARS-CoV-2 infection, due to its unfavorable efficacy and safety profile [110, 111] . Similarly, evidence indicates controversial efficacy of oseltamivir, a sialidase/neuroaminidase inhibitor approved for influenza [112, 113] . In vitro studies have however shown that oseltamivir modulates the sialoglycopshingolipid GM1 and endogenous sialidases [114, 115] . While the use of intravenous immunoglobulins (IVIG) or convalescent plasma led to conflicting results in COVID-19 [118] [119] [120] being therefore not supported by most recent evidence, monoclonal antibodies targeting the SARS-CoV-2 spike protein (bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab) have been approved as monotherapy or combination therapy for early-use in patients with mild to moderate COVID-19 who do not require supplemental oxygen but are at higher risk for severe disease [17, 18, 109] . Although studies are lacking, it has been reported that the interaction between antibodies and FcR would occur in rafts and that raft disruption with MCD may inhibit the binding and phagocytosis of IgG immune complexes [121, 122] . Thus, the integrity of lipid rafts appears to be an essential prerequisite for the success of antibody-based antiviral treatment. The use of azithromycin was initially supposed to improve COVID-19 outcomes when added to usual care [125] . Evidence from pre-clinical studies showed that azithromycin could prevent the interaction between SARS-CoV-2 NTD and gangliosides found in lipid rafts in a manner similar to antimalarials [75]. However, due to potential arrhythmogenic side effects, the use of this antibiotic is solely recommended in COVID-19 cases complicated by bacterial superinfection [126] . 3 Journal Pre-proof reduce viral entry into cultured lung cells [39] and to specifically block the spread of SARS-CoV-2 in human lung tissue in ex vivo experiments [127] . It has also been reported that the expression of TMPRSS2 may be strongly upregulated by androgens in the prostate [128] and by both androgens and glucocorticoids in human lung cells [129] . According to some authors, the strong dependence of TMPRSS2 on androgens may contribute to the increased risk of highly symptomatic forms of COVID-19 observed in men [130] . On the other hand, estrogens are known to modulate the expression of ACE2 [131] , possibly preventing the release of cytokines and the subsequent activation of the innate or acquired immune response, thrombosis and fibrosis, which overall condition a worse COVID-19 outcome [132] . Based on this consideration, several clinical trials are currently underway to investigate the potential benefits of estrogen treatment on COVID-19 (ClinicalTrial.gov ID NCT04359329, NCT04539626, NCT04365127). Raloxifene, a selective estrogen receptor modulator, has also recently been proposed to be repurposed for COVID-19 treatment [133] . Dipeptidyl peptidase-4 (DPP-4), originally known as lymphocyte cell surface protein CD26, has been proposed as another interesting pharmacological target for COVID-19. DPP-4 is expressed in various tissues such as lung, intestine, liver, and kidney. Due to its localization in the plasma membrane and its chemical properties that allow it to bind the S1 domain of SARS-CoV-2 spike proteins, DPP4 has been proposed as an alternative pathway to mediate SARS-CoV-2 cell adhesion [134] . Furthermore, DPP4 is involved in T-cell signalling and functionality [135] . CD26-mediated signalling leading to T-cell activation occurs in lipid rafts through its association with CD45RO [136] . In clinical practice, DPP-4 inhibitors (DPP-4i) are commonly used in patients with type 2 diabetes mellitus (T2DM), including the frail population, due to their efficacy and safety profile [137] . Therefore, patients treated with DPP4i may represent an interesting study population to evaluate whether molecular inhibition of DPP4 could represent an effective pharmacological target J o u r n a l P r e -p r o o f Journal Pre-proof for COVID-19. Although current data from observational studies are inconclusive [135] , a cohort study from Northern Italy found a lower risk of death in patients receiving sitagliptin than in those on standard of care [138] , while a subsequent study from England failed to replicate this result and found a potentially, although small, association between DPP4-i and the risk of death from COVID-19 [139] . Opioid use has been associated with increased susceptibility to COVID-19 as well as morbidity, mortality, and utilization of healthcare resources [140, 141] . Patients receiving long-term opioid therapy may have a weaker immune response and impaired respiratory function [142] [143] [144] , both of which predispose to SARS-CoV-2 infection and severe outcomes. Additionally, large use of opioids in the context of COVID-19 pandemic, as analgesics during orotracheal intubation or for pain management, could expose patients to dangerous drug-drug interactions and side effects [145] . Surprisingly, an unexpectedly low incidence of COVID-19 in patients receiving opioid substitutiontreated patients was reported elsewhere [146, 147] . In this regard, it was hypothesized that the interplay between long-acting opioids or opioid antagonists, ACE-2 signaling, TLR4, and SARS-CoV-2 plays a protective role against the development of COVID-19 [146] . This evidence led to the design of clinical trials on the efficacy of some opioids for the treatment of COVID-19 which are currently ongoing (Clinicaltrials.gov ID NCT04604704; NCT04604678; NCT04365985; NCT04454307). Cholesterol is an important determinant of the lateral organization of k-and µ-opioid receptor within lipid raft domains [148] and may also influence µ-opioid receptor signaling in cell models and analgesia in mice and humans by supporting lipid raft integrity and facilitating G-protein coupling [149] . It was shown that lowering brain cholesterol levels by simvastatin impaired the analgesic effect of opioids in mice, whereas the analgesic effect of opioid was enhanced in mice fed with a high-cholesterol diet. Furthermore, an inverse correlation between cholesterol levels and the J o u r n a l P r e -p r o o f Journal Pre-proof dose of fentanyl used for anesthesia was found, suggesting that these mechanisms may also be applicable to humans [149] . In diagnosed with COVID-19, a reduced relative risk of mortality was associated with fluoxetine use [151] . Previous studies have shown that chronic treatment with antidepressants may enhance adenylyl cyclase activity by partially translocating Galphas (Gαs) from rafts to nonraft domains of the plasma membrane, where they may more easily stimulate adenylyl cyclase [152, 153] . Sustained treatment of cells with various antidepressants, including SSRIs, may lead to an accumulation of these compounds in lipid rafts and correlates with a redistribution of Gαs in the membrane, resulting in lipid rafts disruption [154] . This event may ultimately affect SARS-CoV-2 infection: indeed, some preclinical studies have shown that antidepressants are able to prevent infection of Vero E6 cells with SARS-CoV-2 [155] . Moreover, SSRIs belong to the class of functional inhibitors of acid sphingomyelinase (FIASMA) [156] . Acid sphingomyelinase (ASM) is a lysosomal glycoprotein located in the inner lysosomal membrane. In response to stimulation, ASM is able to migrate to the outer leaflet of the cell membrane and catalyse the hydrolysis of sphingomyelin into ceramide and phosphorylcholine. Sphingomyelin is associated with cholesterol in lipid rafts and is abundant in these structures. ASM inhibition induced by SSRIs may alter the formation of lipid rafts, resulting in a modification of the Journal Pre-proof cell membrane structure. This modification could lead to impairment of lipid raft-mediated endocytosis of SARS-CoV-2, explaining the beneficial role of these molecules on COVID-19 [157] . Chlorpromazine, an antipsychotic, was used to prevent clathrin-mediated endocytosis in vitro [158] . Together with chloroquine, loperamide, and lopinavir, chlorpromazine was shown to inhibit replication of Middle-Estern respiratory syndrome coronavirus (MERS-CoV) and human coronavirus 229E at a 50% effective concentration (EC50) of 3-8 μM [159] . The beneficial effect of chlorpromazine in COVID-19 patients is currently being investigated in a phase III randomized controlled trial [160] . An in vitro experiment has shown that chlorpromazine prevents SARS-CoV infection of HepG2 cells by arresting clathrin-mediated endocytosis [41] , but the effects on lipid raft-dependent endocytosis are unknown. Glycyrrhizin, a natural product with a triterpenoid saponin structure derived from the root of Glycyrrhiza glabra, has been extensively studied for its pharmacological effects, which include anti-inflammatory and antiviral properties. Part of these effects could be explained on the basis of a lipid rafts perturbation. Specifically, thanks to its saponin structure, glycyrrhizin can interact with membrane cholesterol and reduce membrane fluidity, preventing the movement of viral receptors within the membrane and the formation of fusion pores [161] . responsible for the efflux of cholesterol, iii) reducing the supply of cholesterol and sphingolipid by inhibiting their biosynthesis [9]. The first approach could be pursued by using the food additive MβCD, which has already been shown to inhibit the entry of HIV into host cells and to have anti-inflammatory properties. Disruption of raft cholesterol could prevent translocation of ACE2 to the apical pole of epithelial cells, thereby dramatically reducing its availability for activation of the SARS-CoV-2 receptor. Priming of furin is also dependent on cholesterol [162] . Preliminary evidence of a possible beneficial effect of lipid-lowering therapy based on MβCD or mevastatin against coronaviruses has been described for infectious bronchitis virus (IBV) [163] and for porcine deltacoronavirus (PDCoV) [164] , suggesting a possible role also in the context of SARS-CoV-2. By using in vitro cell models expressing ACE2, researchers showed that depletion of cholesterol by MβCD was associated with a significant decrease in the number of bindings to the ACE2-spike protein, along with a dose-dependent reduction in ACE2 expression that resulted in reduced SARS-CoV replication [165] . In another study on coronavirus infectious bronchitis [45] , it was reported that MβCD or mevastatin-induced disruption of lipid rafts reduced the expression of structural viral proteins associated with cav-1 in Vero cells, limiting viral infectivity in the early stage of infection. However, treatment with MCD was ineffective in the late stage and did not prevent virion release. MCD depletes membrane cholesterol in a nonspecific manner and act on both raft and nonraft domains; in addition, the compound is also capable of altering ion permeability and inducing cytotoxicity. Phytosterols, fumonisin, myriocin and sphingomyelinase could also affect viral infectivity by interacting with other lipid components of lipid rafts such as sphingolipids [166, 167] . The second strategy could be achieved by stimulating of the expression of ABCA1 and G1 using liver X receptor (LXR) agonists or heterologous overexpression of these transporters [13, 168] . The last option could be achieved by using inhibitors of cholesterol and sphingolipid biosynthesis, such as statins and miglustat, respectively [169] . In addition to inhibiting the cholesterol biosynthesis pathway and disrupting lipid raft composition, the use of statins may also lead to a J o u r n a l P r e -p r o o f Journal Pre-proof reduction in CD147 translocation to the cell surface [170] . CD147 is a transmembrane glycoprotein associated with lipid rafts and plays a critical role in SARS-CoV-2 infection by promoting viral entry and modulating T cell activation. Additionally, it can increase the expression of GLUT1 transporters and shift cellular metabolism towards a glycolytic pathway [171] . As cellular cholesterol increases with age, inflammation, smoking, and metabolic disorders (e.g., obesity and diabetes), the plasma membrane may become a more favorable environment for SARS-CoV-2 engagement, contributing to the severity of COVID-19 [171, 172] . Statins may have further benefits in COVID-19 treatment thanks to their anticoagulant and anti-inflammatory effects. The use of statins and/or anti-hypertensives was associated with a 32% lower mortality rate in patients hospitalized for COVID-19 and with a history of cardiovascular disease and/or hypertension [173] . However, a recent multicenter randomized clinical trial comparing the efficacy of atorvastatin vs placebo performed in patients with COVID-19 admitted to the intensive care unit (ICU) showed no effect of this statin on the composite outcome of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all cause mortality within 30 days, compared with placebo [174] . This narrative review aims to highlight the contribution to lipid raft perturbation of already commercialized drugs, which could potentially be useful as a rationale for drug repurposing or explain different severities or prognoses of COVID-19 disease in specific patients' groups. The crucial role of lipid rafts in viral infections as viral entry pathways and in immune responses as immune synapses make these domains a double-edged sword in the pathogenesis of COVID-19, as they contribute to both viral spread and inflammation, to mitigate the infection [13] . Although there is not yet clear evidence linking lipid raft disruption to the antiviral response associated with COVID-19, some evidence highlights that lipid rafts may represent the site of initial binding, activation, internalization, and cell-to-cell transmission of SARS-CoV-2 [13] . Moreover, dysregulation of the immune response leading to uncontrolled inflammation, which also appears to be mediated by lipid rafts, is a key feature of COVID-19 [176, 177] . It has been shown that disruption of raft lipid content with membrane cholesterol reduction prevents coronavirus entry into target cells [2, 45] . Lipid modification may also affect the translocation and recruitment of proteins that play a central role in either SARS-CoV-2 entry, such as ACE2, or immune synapse formation [165, 170] . Proteins located within lipid rafts may be targeted by anti-COVID-19 drugs including steroids, antimalarials, immunosuppressants, antiviral agents, or heparin [40, 85, 86, 92, 96, 98, 100, 108, 116, 121, 122, 124, [178] [179] [180] [181] , Table 1 . Adjunctive therapies, such as estrogens, lipid-lowering or glucose-lowering drugs, may also lead to better J o u r n a l P r e -p r o o f Journal Pre-proof COVID-19 outcomes, although it is unclear whether such effects may depend on the protective mechanisms exerted on the components of the lipid rafts [131, 182] . This intricate scenario underlines the central role of lipid rafts in SARS-CoV-2 infection and suggests that combined strategies targeting these microdomains and aimed at simultaneously preventing viral entry and modulating the immune response may prove highly beneficial for the treatment of the disease. Indeed, further research is needed to better unravel the extent to which lipid rafts contribute to COVID-19 pathogenesis and may be selected as ideal candidates for therapy. Interaction of pathogens with host cholesterol metabolism Lipid rafts in immune signalling: current progress and future perspective Dysfunctional Coagulation in COVID-19: From Cell to Bedside The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions Lipid rafts are essential for release of phosphatidylserineexposing extracellular vesicles from platelets Tissue Factor, Lipid Rafts, and Microparticles Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation Evaluation and Treatment Coronavirus (COVID-19) -StatPearls -NCBI Bookshelf Overview of Covid-19; its prevention and management in the light of Unani medicine of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Targeting Lipid Rafts-A Potential Therapy for COVID-19 Lipid rafts are involved in SARS-CoV entry into Vero E6 cells Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates Update to living WHO guideline on drugs for covid-19 AIFA Italian Medicines Agency. Medicines usable for treatment of COVID-19 disease 2021 Therapeutics and COVID-19: living guideline 2022 The fluid mosaic model of the structure of cell membranes Membrane lipids: Where they are and how they behave Lipid Sorting in Epithelial Cells Functional rafts in cell membranes Rafts defined: A report on the Keystone symposium on lipid rafts and cell function The mystery of membrane organization: Composition, regulation and roles of lipid rafts Intracellular Lipid Flux and Membrane Microdomains as Organizing Principles in Inflammatory Cell Signaling Functional roles of gangliosides in Neurodevelopment: An overview of recent advances Insolubility of lipids in Triton X-100: Physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts) Evidence for the involvement of lipid rafts localized at the ER-mitochondria associated membranes in autophagosome formation Clathrin-and non-clathrin-mediated endocytic regulation of cell signalling Molecular mechanism and physiological functions of clathrinmediated endocytosis The multiple faces of caveolae Isoforms of caveolin-1 and caveolar structure A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 c-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo A novel model of cholesterol efflux from lipid-loaded cells Mechanisms of receptor/coreceptor-mediated entry of enveloped viruses An Overview of Their Replication and Pathogenesis SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER Lipid-mediated endocytosis Human Coronavirus 229E Binds to CD13 in Rafts and Enters the Cell through Caveolae The important role of lipid raftmediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain Putative caveolin-binding sites in SARS-CoV proteins Caveolae meet endosomes: A stable relationship? Endocytic Crosstalk: Cavins, Caveolins, and Caveolae Regulate Clathrin-Independent Endocytosis Plasma membrane rafts play a critical role in HIV-1 assembly and release Influenza Virus Can Enter and Infect Cells in the Absence of Clathrin-Mediated Endocytosis Cholesterol lowering: Role in cancer prevention and treatment Encyclopedic Reference of Immunotoxicology The shedding activity of ADAM17 is sequestered in lipid rafts The effect of surface topography on early NFκB signaling in macrophages Il-6 trans-signaling via the soluble IL-6 receptor: Importance for the proinflammatory activities of IL-6 Macrophage ABCA1 reduces MyD88-dependent toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 Mitogenactivated protein kinase and induces cathepsin K A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio A New Perspective on Th17/Treg Cell Imbalance in Systemic Lupus Erythematosus Ordered just so: lipid rafts and lymphocyte function Limited cholesterol depletion causes aggregation of plasma membrane lipid rafts inducing T cell activation Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes Dietary supplementation with eicosapentaenoic acid, but not with other long polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 Effects of Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": A transcriptional informatics analysis with validation Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis Pulmonary surfactant in health and human lung diseases: State of the art Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification A pilot study on the preventative potential of alpha-cyclodextrin and hydroxytyrosol against SARS-CoV-2 transmission Autoimmunity as the comet tail of COVID-19 pandemic Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease Dexamethasone in Hospitalized Patients with Covid-19 -The RECOVERY Collaborative Group WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Adjunct Immunotherapies for 7 Glucocorticoids Alter the Lipid and Protein Composition of Membrane Rafts of a Murine T Cell Hybridoma Glucocorticoid Receptors within Lipid Rafts Activate a MAPK-Dependent, Nongenomic Signaling Pathway To Limit Gap Junction Intercellular Communication and Proliferation in Neural Stem Cells Induction of proinflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: antiinflammatory strategies IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 IL-2 induces conformational changes in its preassembled receptor core, which then migrates in lipid raft and binds to the cytoskeleton meshwork Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome Lipid rafts and caveolin-1 coordinate interleukin-1β (IL-1β)-dependent activation of NFκB by controlling endocytosis of Nox2 and IL-1β receptor 1 from the plasma membrane Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS Greasing Their Way: Lipid Modifications Determine Protein Association with Membrane Rafts Re-evaluation of antimalarials in treating rheumatic diseases: Reappreciation and insights into new mechanisms of action PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine Effect of hydroxychloroquine on the lipid profile of patients with sjögren syndrome Hydroxychloroquine reduces lowdensity lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications COVID-19 Treatment Guidelines Panel. National Institutes of Health Update to living systematic review on drug treatments for covid-19 Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study Oseltamivir for coronavirus illness: Post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from Modulation of opioid analgesia, tolerance and dependence by G(s)-coupled, GM1 ganglioside-regulated opioid receptor functions Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice Immunopathology of Hyperinflammation in COVID-19 Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19 Early Convalescent Plasma for High-Risk Outpatients with Covid-19 Differential requirement of lipid rafts for FcγRIIA mediated effector activities Phagocytosis of IgG-Coated Polystyrene Beads by Macrophages Induces and Requires High Membrane Order Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Heparin suppresses lipid raft-mediated signaling and platform trial Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2 Androgen receptor and androgendependent gene expression in lung Impact of sex and gender on COVID-19 outcomes in Europe Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? Repurposing the J o u r n a l P r e -p r o o f Journal Pre-proof estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 DPP-4 inhibition and COVID-19: From initial concerns to recent expectations CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO The safety of gliptins : updated data Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England COVID-19 outcomes among adult patients treated with long-term opioid therapy for chronic non-cancer pain in the USA: a retrospective Incidence, reversal, and prevention of opioid-induced respiratory depression The Role of Opioid Receptors in Immune System Function The use of prescribed opioid analgesics & the risk of serious infections Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes Therapeutic potential of long-acting opioids and opioid antagonists for SARS-CoV-2 infection Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Dynamic lateral organization of opioid receptors (kappa, mu wt and mu N40D ) in the plasma membrane at the nanoscale level Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants Treatment of C6 glioma cells and rats with antidepressant drugs increases the detergent extraction of G(s alpha) from plasma membrane Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound Antidepressants Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, Gαs The acid sphingomyelinase/ceramide system in COVID-19 Functional inhibitors of acid sphingomyelinase (FIASMAs) Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes Screening of an FDA-approved compound library identifies four smallmolecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture Encephale 2020 Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Statins and PCSK9 inhibitors: What is their role in coronavirus disease The Important Role of Lipid Raft-Mediated Attachment in the Infection of Cultured Cells by Coronavirus Infectious Bronchitis Virus Beaudette Strain Cholesterol is important for the entry process of porcine deltacoronavirus Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2 Sphingolipids and lipid rafts: Novel concepts and methods of analysis The Role J o u r n a l P r e -p r o o f Journal Pre-proof of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis Mechanistic convergence and shared therapeutic targets in Niemann-Pick disease Selective Inhibition of T Cell Activation Via CD147 Through Novel Modulation of Lipid Rafts Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial PCSK9 at the crossroad of cholesterol metabolism and immune function during infections Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure Microdomains, Inflammation, and Atherosclerosis Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by Pglycoprotein Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation The assembly of GM1 glycolipidand cholesterol-enriched raft-like membrane microdomains is important for giardial encystation Abbreviations: MβCD: methyl-β-cyclodextrin; ACE2: angiotensin converting enzyme 2; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2; PCSK9: proprotein convertase subtilisin/kexin type 9; TLR: Toll-like receptors; IL-6R: interleukin-6 receptor; IL-1interleukin-1 beta; IVIG: intravenous immunoglobulins; moAbs: monoclonal antibodies; FcR: fragment crystallizable receptor; JAKi: Janus kinase inhibitor; STAT: signal transducer and activator of transcription; ABCA1: ATP-binding cassette A1; ER: endoplasmic reticulum; NPC1: Niemann-Pick C1; MAP: mitogen-activated protein; EGFR: endothelial growth factor receptor The authors declare that they have no conflict of interest.